<DOC>
	<DOCNO>NCT00537342</DOCNO>
	<brief_summary>The objective trial evaluate clinical effectiveness administration depigmented polymerized allergen extract Olea europaea rhinitis allergic rhinoconjunctivitis</brief_summary>
	<brief_title>Immunotherapy With Depigmented Polymerized Allergen Extract Olea Europaea ( GPIT )</brief_title>
	<detailed_description>Immunotherapy specific treatment allergic disease . Unlike conventional pharmacological treatment , immunotherapy treatment could modify natural course allergic disease . This prospective double-blind placebo control study two arm treatment : placebo active .</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<criteria>Positive suggestive clinical history allergic seasonal rhinitis rhinoconjunctivitis Patients gender &gt; 18 year old Positive prick test result use non modify Olea europaea allergen extract ( wheal size &gt; 3mm2 ) Specific IgE Olea europaea Written inform consent Use immunotherapy last four year . Any contraindication use immunotherapy accordance European Allergy Clinical Immunology Immunotherapy Subcommittee criterion : Treatment ÃŸblockers Coexistence immunopathological disease ( e.g . liver , kidney , nervous system , thyroid gland , rheumatic disease ) autoimmune mechanisms play role Patients suffer immune deficiency Patients serious psychiatric / psychological disturbance In addition , follow consider exclusion criterion : Pregnant or/ lactation patient Patients aspirin intolerance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>Allergoid</keyword>
	<keyword>Depigmented</keyword>
	<keyword>Polymerized</keyword>
	<keyword>Allergen-extract</keyword>
	<keyword>Rhinoconjunctivitis</keyword>
</DOC>